NEOTHETICS, INC. (NASDAQ:NEOT) Files An 8-K Regulation FD Disclosure

Item 7.01Regulation FD Disclosure.

A copy of a slide presentation that Neothetics, Inc. (NASDAQ:
NEOT) (the Company) intends to present to investors is attached
to this Current Report on Form 8-K as Exhibit 99.1 and is
incorporated herein solely for purposes of this Item 7.01
disclosure.

The information in this Item 7.01, including Exhibit 99.1, is
being furnished and shall not be deemed to be filed for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended,
and shall not be deemed incorporated by reference into any
registration statement or other document filed to the Securities
Act of 1933, as amended, except as shall be expressly set forth
by specific reference in such filing.

(d) Exhibits.

About NEOTHETICS, INC. (NASDAQ:NEOT)

Neothetics, Inc. is a clinical-stage specialty pharmaceutical company, which develops therapeutics. The Company focuses on localized fat reduction and body contouring. It focuses on the development of LIPO-202 for the reduction of central abdominal bulging due to subcutaneous fat in non-obese patients. It has completed Phase II development of LIPO-202. LIPO-202 is administered in a subcutaneous injection procedure that activates a natural metabolic process to shrink fat cells, without killing them, resulting in localized fat reduction, measurable results within four weeks and minimal risk with no downtime. The Company is developing a product candidate, LIPO-102, an injectable form of a combination of salmeterol xinafoate and fluticasone propionate. LIPO-102 is indicated for the treatment of the orphan indication of symptomatic exophthalmos, or protrusion of the eye from the orbit, associated with thyroid-related eye disease caused by the expansion of fat and muscle behind the eye.

NEOTHETICS, INC. (NASDAQ:NEOT) Recent Trading Information

NEOTHETICS, INC. (NASDAQ:NEOT) closed its last trading session up +0.09 at 1.69 with 567,566 shares trading hands.